Checkpoint Other Operating Expenses from 2010 to 2024
| CKPT Stock | USD 4.28 0.18 4.39% |
Other Operating Expenses | First Reported 2015-03-31 | Previous Quarter 6.7 M | Current Value 9.7 M | Quarterly Volatility 5.3 M |
Check Checkpoint Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Checkpoint Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 102.1 K, Depreciation And Amortization of 159.5 K or Interest Expense of 5.2 M, as well as many indicators such as Price To Sales Ratio of 438, Dividend Yield of 0.0 or Days Sales Outstanding of 168. Checkpoint financial statements analysis is a perfect complement when working with Checkpoint Therapeutics Valuation or Volatility modules.
Checkpoint | Other Operating Expenses |
Latest Checkpoint Therapeutics' Other Operating Expenses Growth Pattern
Below is the plot of the Other Operating Expenses of Checkpoint Therapeutics over the last few years. Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Checkpoint Therapeutics. It is also known as Checkpoint Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. It is expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production. Checkpoint Therapeutics' Other Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Checkpoint Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Other Operating Expenses | 10 Years Trend |
|
Other Operating Expenses |
| Timeline |
Checkpoint Other Operating Expenses Regression Statistics
| Arithmetic Mean | 28,685,508 | |
| Geometric Mean | 24,637,288 | |
| Coefficient Of Variation | 58.03 | |
| Mean Deviation | 13,856,944 | |
| Median | 24,500,000 | |
| Standard Deviation | 16,645,008 | |
| Sample Variance | 277.1T | |
| Range | 44.7M | |
| R-Value | 0.84 | |
| Mean Square Error | 86.6T | |
| R-Squared | 0.71 | |
| Significance | 0.000081 | |
| Slope | 3,135,812 | |
| Total Sum of Squares | 3878.8T |
Checkpoint Other Operating Expenses History
About Checkpoint Therapeutics Financial Statements
Checkpoint Therapeutics shareholders use historical fundamental indicators, such as Other Operating Expenses, to determine how well the company is positioned to perform in the future. Although Checkpoint Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Checkpoint Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Checkpoint Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Other Operating Expenses | 52.3 M | 39.3 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Checkpoint Stock Analysis
When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.